Hedge fund manager wins U.S. drug patent challenges

[+]Enlarge



 



A federal tribunal ruled that two patents related to Celegene’s blood cancer drug Revlimid are invalid.
Credit: Newscom



Hedge fund manager J. Kyle Bass’s controversial campaign of challenging the validity of U.S. drug patents scored a pair o...

Read full post here:
http://skpsoft.com/view/science+news/hedge-fund-manager-wins-u-s-drug-patent-challenges/